VKTX250103C70000
- 0.16
- 0.000.00%
Viking Therapeutics Newsroom
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Why Viking Therapeutics (VKTX) Is the Biotech With Biggest Upside Potential
Viking Therapeutics' VK2735: A Promising Contender in the Weight-Loss Market With Superior Efficacy Profile
Here's How Much $1000 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Fast-Growing M&A Firm Opens Dallas Office, Continues Expansion in Texas
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $105
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
Positive Outlook for Viking Therapeutics Amid Promising Trial Developments
Viking Therapeutics' Oral-2735 Could Differentiate Asset, Says JPMorgan
This Insider Has Just Sold Shares In Viking Therapeutics
Viking Therapeutics Analyst Ratings
Express News | Viking Therapeutics Announces Initiation of Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients With Obesity